Login to Your Account


Corcept Therapeutics cedes PMD bid after fourth phase III miss; targets oncology

By Jennifer Boggs
Managing Editor

Thursday, May 8, 2014
Corcept Therapeutics Inc. still has hopes of building a portfolio based on cortisol blocking drug mifepristone, but it looks like psychotic major depression (PMD) is off the table after the monitoring committee reported that an ongoing phase III trial was unlikely to hit its primary endpoint, defined as a rapid and sustained reduction in psychotic symptoms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription